ibrutinib (Imbruvica) is the general drug of target therapy. A portion of people don't respond to this drug, for them who respond, resistance may occur. In 2017, Acalabrutinib was approved by FDA. It's a second-generation BTK inhibitor, for treatment of adults with mantle cell lymphoma whose cancer has progressed after receiving at least one prior therapy. Lately doctor Manel Esteller from University of Barcelona, presents an epigenetic drug capable of slowing down cell growth in mantle cell lymphoma, but the clinical trial is expected to commence in 2019.